A 24-year-old woman from Mumbai presents with vaginal discharge and pelvic pain for 10 days. She reports a new sexual partner 2 weeks ago. On examination, mucopurulent cervical discharge is noted with cervical motion tenderness and adnexal tenderness bilaterally. Gram stain of cervical discharge is negative for gram-negative diplococci. Nucleic acid amplification test (NAAT) for *Chlamydia trachomatis* is positive; NAAT for *Neisseria gonorrhoeae* is negative. What is the most appropriate antimicrobial regimen?

Explanation

## Diagnosis and Clinical Presentation **Key Point:** Mucopurulent cervical discharge, pelvic inflammatory disease (PID) signs (cervical motion tenderness, adnexal tenderness), and positive NAAT for *Chlamydia trachomatis* with negative gonococcal NAAT confirm uncomplicated chlamydial cervicitis. ## Organism Identification | Feature | *Chlamydia trachomatis* | *Neisseria gonorrhoeae* | |---------|------------------------|------------------------| | **Gram stain** | Negative (intracellular) | Gram-negative diplococci | | **Discharge type** | Mucopurulent, scanty | Purulent, thick, greenish-yellow | | **NAAT result** | Positive | Negative | | **Incubation period** | 7–14 days | 2–5 days | **Clinical Pearl:** The negative Gram stain rules out gonococcal urethritis; chlamydia is an obligate intracellular pathogen and does not stain well with Gram stain. ## Treatment Guidelines for Uncomplicated Chlamydial Infection **High-Yield:** CDC and WHO guidelines (2023) for uncomplicated chlamydial cervicitis: | Regimen | Dose | Duration | Efficacy | Notes | |---------|------|----------|----------|-------| | **Doxycycline** | 100 mg BD | 7 days | >95% | First-line | | **Azithromycin** | 1 g single | Single dose | 90–95% | Alternative; resistance emerging | | **Ceftriaxone + Azithromycin** | 250 mg IM + 1 g oral | Single doses | For gonorrhea co-infection | Not needed here (gonorrhea negative) | | **Ciprofloxacin** | 500 mg BD | 7 days | Outdated | No longer recommended; resistance | **Mnemonic: DOX** — **D**oxycycline is the **O**ptimal **X**-choice for chlamydia monotherapy ## Why Doxycycline Over Alternatives 1. **Doxycycline 100 mg BD × 7 days:** - First-line agent per CDC/WHO - >95% cure rate - Excellent intracellular penetration - Cost-effective - Minimal resistance 2. **Why NOT azithromycin alone:** - Although efficacious, resistance is emerging (especially in macrolide-resistant strains) - Reserved for pregnant women or doxycycline allergy - Single-dose convenience offset by lower cure rates in some populations 3. **Why NOT ceftriaxone + azithromycin:** - This combination is for **dual therapy** in suspected gonococcal co-infection - NAAT for gonorrhea is negative; ceftriaxone is unnecessary - Overtreatment increases resistance and cost 4. **Why NOT ciprofloxacin:** - Fluoroquinolones are no longer recommended for chlamydia due to high resistance - Outdated regimen ## Partner Management and Follow-up **Clinical Pearl:** Sexual partners should be treated empirically with the same regimen (doxycycline 100 mg BD × 7 days) without waiting for test results if exposure was within 60 days. Test of cure is not recommended; repeat testing at 3 weeks can be done if symptoms persist. [cite:CDC STI Treatment Guidelines 2021; Harrison 21e Ch 163]